Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4018-4026

  Coen, Muireann ^a,b   Bodkin, Jennifer ^a   Power, Damla ^a   Bubb, William A ^a   Himmelreich, Uwe ^a,c   Kuchel, Philip W ^a   Sorrell, Tania C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ACETIC ACID; ALCOHOL; AMPHOTERICIN B; ANTIFUNGAL AGENT; APOTHECON; CASPOFUNGIN; FORMIC ACID; FUMARIC ACID; GLUCOSE; GLYCEROL; LACTIC ACID; PYRUVIC ACID; SUCCINIC ACID; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH MICRODILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; CULTURE MEDIUM; DILUTION; DRUG RESPONSE; EVALUATION; FUNGAL METABOLISM; FUNGAL STRAIN; FUNGUS; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROMETER; TRICHOSPORON BEIGELII;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; INDICATOR DILUTION TECHNIQUES; KINETICS; MICROBIAL SENSITIVITY TESTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES; TRICHOSPORON;

EID: 33845244538     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00439-06     Document Type: Article

References (22)

1. Arthington-Skaggs, B. A., H. Jradi, T. Desai, and C. J. Morrison. 1999. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J. Clin. Microbiol. 37:3332-3337.
2. Bubb, W. A., L. C. Wright, M. Cagney, R. T. Santangelo, T. C. Sorrell, and P. W. Kuchel. 1999. Heteronuclear NMR studies of metabolites produced by Cryptococcus neoformans in culture media: identification of possible virulence factors. Magn. Reson. Med. 42:442-453.
3. Chen, J., Z. Wan, and R. Li. 2004, Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species. J. Clin. Microbiol. 42:1790-1793.
4. Cuenca-Estrella, M., C. B. Moore, F. Barchiesi, J. Bille, E. Chryssanthou, D. W. Denning, J. P. Donnelly, F. Dromer, B. Dupont, J. H. Rex, M. D. Richardson, B. Sancak, P. E. Verweij, and J. L. Rodriguez-Tudela. 2003. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9:467-474.
5. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, M. A. Pfaller, M. Rinaldi, J. L. Rodriguez-Tudela, and P. E. Verwey. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
6. Himmelreich, U., T. E. Dzendrowskyj, C. Allen, S. Dowd, R. Malik, B. P. Shehan, P. Russell, C. E. Mountford, and T. C. Sorrell. 2001. Cryptococcomas distinguished from gliomas with MR spectroscopy: an experimental rat and cell culture study. Radiology 220:122-128.
7. Himmelreich, U., R. L. Somorjai, B. Dolenko, H. M. Daniel, and T. C. Sorrell. 2005. A rapid screening test to distinguish between Candida albicans and Candida dubliniensis using NMR spectroscopy. FEMS Microbiol. Lett. 251:327-332.
8. Himmelreich, U., R. L. Somorjai, B. Dolenko, O. C. Lee, H. M. Daniel, R. Murray, C. E. Mountford, and T. C. Sorrell. 2003. Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy. Appl. Environ. Microbiol. 69:4566-4574.
9. Kretschmar, M., T. Nichterlein, P. Kuntz, and H. Hof. 1996. Rapid detection of susceptibility to fluconazole in Candida species by a bioluminescence assay of intracellular ATP. Diagn. Microbiol. Infect. Dis. 25:117-121.
10. Liao, R. S., R. P. Rennie, and J. A. Talbot. 2002. Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates. Antimicrob. Agents Chemother. 46:3236-3242.
11. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
13. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
14. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol. 42:3142-3146.
15. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
16. Pina-Vaz, C., S. Costa-de-Oliveira, A. G. Rodrigues, and A. Espinel-Ingroff. 2005. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J. Clin. Microbiol. 43:4674-4679.
17. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
18. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
19. Riesselman, M. H., K. C. Hazen, and J. E. Cutler. 2000. Determination of antifungal MICs by a rapid susceptibility assay. J. Clin. Microbiol. 38:333-340.
20. Stevens, D. A., M. Espiritu, and R. Parmar. 2004, Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
21. Van Zijl, P., A. O'Neil, M. Johnson, S. Mori, and R. E. Hurd. 1995. Magic-angle-gradient double-quantum-filtered COSY. J. Magn. Reson. 113A:265-270.
22. Wiederhold, N. P., D. P. Kontoyiannis, R. A. Prince, and R. E. Lewis. 2005. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. 49:5146-5148.